ArticleNeurosurgical review2026
Efficacy of N-butyl-2-cyanoacrylate-based middle meningeal artery embolization for preventing recurrence of chronic subdural hematoma in patients aged 65 years and older.
Article in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intraindividual histopathological comparison of embolized and nonembolized territories in recurrent chronic subdural hematoma after middle meningeal artery embolization: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the efficacy and safety of N-butyl-2-cyanoacrylate (NBCA)-based middle meningeal artery embolization (MMAE) in preventing recurrence of chronic subdural hematoma (CSDH) in elderly patients. We retrospectively analyzed 221 patients aged ≥ 65 years who underwent burr hole surgery (BHS) with or without adjunctive MMAE between April 2023 and March 2025. Clinical, radiological, and perioperative variables were assessed, with the primary outcome being 90-day recurrence requiring retreatment. Among the cohort, 92 patients received BHS with MMAE and 129 underwent BHS alone. The median age was 82.0 years (IQR 77.0-86.0), and 64.3% were male. The overall recurrence rate was 12.7% (n = 28). Multivariate analysis identified male sex as an independent risk factor for recurrence (OR 4.95, 95% CI 1.61-21.7, P = 0.004), while acute hemorrhage within the hematoma (OR 0.19, 95% CI 0.01-0.99, P = 0.048) and BHS combined with MMAE (OR 0.37, 95% CI 0.13-0.94, P = 0.04) were associated with reduced recurrence risk. Subgroup analyses suggested that MMAE was particularly effective in male patients and in those with septated hematomas. Additionally, the BHS with MMAE group experienced fewer symptomatic complications (0% vs. 4.6%, P = 0.044) and required postoperative Goreisan far less frequently (16.5% vs. 92.3%, P < 0.001). These findings support that NBCA-based MMAE is associated with lower odds of recurrence and fewer symptomatic complications in elderly patients with CSDH, especially in anatomically and clinically favorable subgroups.
Indexed as
Identifiers
41495340What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.